1 – 3 of 3
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B) : 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial
2024) In The Lancet Haematology(
- Contribution to journal › Article
- 2023
-
Mark
Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B
(
- Contribution to journal › Article
- 2019
-
Mark
Factor VIII : Long-established role in haemophilia A and emerging evidence beyond haemostasis
(
- Contribution to journal › Scientific review